Q3 2025 13F Holders as of 9/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.00001
-
Shares outstanding
-
62.2M
-
Number of holders
-
273
-
Total 13F shares, excl. options
-
70.7M
-
Shares change
-
-293K
-
Total reported value, excl. options
-
$4.7B
-
Value change
-
+$3.97M
-
Put/Call ratio
-
0.3
-
Number of buys
-
123
-
Number of sells
-
-148
-
Price
-
$66.43
Significant Holders of Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) as of Q3 2025
321 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 as of Q3 2025.
Protagonist Therapeutics, Inc - Common Stock, par value $0.00001 (PTGX) has 273 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 70.7M shares
.
Largest 10 shareholders include BlackRock, Inc. (9.4M shares), FARALLON CAPITAL MANAGEMENT LLC (6.2M shares), RTW INVESTMENTS, LP (5.76M shares), VANGUARD GROUP INC (4.26M shares), STATE STREET CORP (3.17M shares), BVF INC/IL (2.56M shares), JOHNSON & JOHNSON (2.45M shares), WELLINGTON MANAGEMENT GROUP LLP (1.91M shares), UBS Group AG (1.9M shares), and Deep Track Capital, LP (1.72M shares).
This table shows the top 273 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.